Year 2016 / Volume 108 / Number 6
Special Article
Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult

332-363

DOI: 10.17235/reed.2016.4389/2016

Fermín Mearin, Constanza Ciriza, Miguel Mínguez, Enrique Rey, Juan José Mascort, Enrique Peña, Pedro Cañones, Javier Júdez,

Abstract
In this Clinical Practice Guideline we discuss the diagnostic and therapeutic approach of adult patients with constipation and abdominal complaints at the confluence of the irritable bowel syndrome spectrum and functional constipation. Both conditions are included among the functional bowel disorders, and have a significant personal, healthcare, and social impact, affecting the quality of life of the patients who suffer from them. The first one is the irritable bowel syndrome subtype, where constipation represents the predominant complaint, in association with recurrent abdominal pain, bloating, and abdominal distension. Constipation is characterized by difficulties with or low frequency of bowel movements, often accompanied by straining during defecation or a feeling of incomplete evacuation. Most cases have no underlying medical cause, and are therefore considered as a functional bowel disorder. There are many clinical and pathophysiological similarities between both disorders, and both respond similarly to commonly used drugs, their primary difference being the presence or absence of pain, albeit not in an “all or nothing” manner. Severity depends not only upon bowel symptom intensity but also upon other biopsychosocial factors (association of gastrointestinal and extraintestinal symptoms, grade of involvement, and perception and behavior variants). Functional bowel disorders are diagnosed using the Rome criteria. This Clinical Practice Guideline has been made consistent with the Rome IV criteria, which were published late in May 2016, and discuss alarm criteria, diagnostic tests, and referral criteria between Primary Care and gastroenterology settings. Furthermore, all the available treatment options (exercise, fluid ingestion, diet with soluble fiber-rich foods, fiber supplementation, other dietary components, osmotic or stimulating laxatives, probiotics, antibiotics, spasmolytics, peppermint essence, prucalopride, linaclotide, lubiprostone, biofeedback, antidepressants, psychological therapy, acupuncture, enemas, sacral root neurostimulation, surgery) are discussed, and practical recommendations are made regarding each of them.
Share Button
New comment
Comments

06/11/2019 2:41:21
GOSTARIA DE ENTENDER MAIS SOBRE O ASSUNTO,


16/05/2018 18:51:32
ok


References
1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91. PMID: 16678561.
2. Mearin F, Lacy B, Chang L, Chey W, Lembo A, Simrem M, et al. Functional bowel disorders: Rome IV. En prensa. 2015.
3. Rey E, Balboa A, Mearin F. Chronic Constipation, Irritable Bowel Syndrome With Constipation and Constipation With Pain/Discomfort: Similarities and Differences. American Journal of Gastroenterology. 2014;109(6):876-84. PMID: 24589666.
4. Wong RK, Palsson OS, Turner MJ, Levy RL, Feld AD, von Korff M, et al. Inability of the Rome III Criteria to Distinguish Functional Constipation From Constipation-Subtype Irritable Bowel Syndrome. American Journal of Gastroenterology. 2010;105(10):2228-34. PMID: 20502449.
5. Bharucha AE, Locke GR, Zinsmeister AR, Seide BM, McKeon K, Schleck CD, et al. Differences between painless and painful constipation among community women. American Journal of Gastroenterology. 2006;101(3):604-12. PMID: 16464225.
6. Kamm MA, Muller-Lissner S, Talley NJ, Tack J, Boeckxstaens G, Minushkin ON, et al. Tegaserod for the treatment of chronic constipation: A randomized, double-blind, placebo-controlled multinational study. American Journal of Gastroenterology. 2005;100(2):362-72. PMID: 15667494.
7. Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Alimentary Pharmacology & Therapeutics. 2002;16(11):1877-88. PMID: 12390096.
8. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. American Journal of Gastroenterology. 2008;103(1):170-7. PMID: 17916109.
9. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Alimentary Pharmacology & Therapeutics. 2009;29(3):329-41. PMID: 19006537.
10. Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, et al. Two Randomized Trials of Linaclotide for Chronic Constipation. New England Journal of Medicine. 2011;365(6):527-36. PMID: 21830967.
11. Johnston JM, Kurtz CB, MacDougall JE, Lavins BJ, Currie MG, Fitch DA, et al. Linaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation. Gastroenterology. 2010;139(6):1877-U139. PMID: 20801122.
12. Vandvik PO, Wilhelmsen I, Ihlebaek C, Farup PG. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Alimentary Pharmacology & Therapeutics. 2004;20(10):1195-203. PMID: 15569123.
13. Whitehead WE, Palsson OS, Levy RR, Feld AD, Turner M, Von Korff M. Comorbidity in irritable bowel syndrome. American Journal of Gastroenterology. 2007;102(12):2767-76. PMID: 17900326.
14. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scandinavian Journal of Gastroenterology. 1997;32(9):920-4. PMID: 9299672.
15. Bharucha AE, Wald AM. Anorectal Disorders. American Journal of Gastroenterology. 2010;105(4):786-94. PMID: 20372131.
16. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Alimentary Pharmacology & Therapeutics. 2007;25(5):599-608. PMID: 17305761.
17. Posserud I, Syrous A, Lindstrom L, Tack J, Abrahamsson H, Simren M. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology. 2007;133(4):1113-23. PMID: 17919487.
18. Ng C, Danta M, Kellow J, Badcock CA, Hansen R, Malcolm A. Attenuation of the colorectal tonic reflex in female patients with irritable bowel syndrome. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2005;289(3):G489-G94. PMID: 15905412.
19. Burgell RE, Scott SM. Rectal Hyposensitivity. Journal of Neurogastroenterology and Motility. 2012;18(4):373-84. PMID: 23105997.
20. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Alimentary Pharmacology & Therapeutics. 2002;16(6):1171-85. PMID: 12030961.
21. Mearin F, Perello A, Perona M. Quality of life in patients with irritable bowel syndrome. Gastroenterologia y hepatologia. 2004;27 Suppl 3:24-31.
22. Everhart JE, Ruhl CE. Burden of Digestive Diseases in the United States Part II: Lower Gastrointestinal Diseases. Gastroenterology. 2009;136(3):741-54. PMID: 19166855.
23. Tack J, Stanghellini V, Mearin F, Yiannakou Y, Layer P, Coffin B, et al. Economic burden of moderate to severe Irritable Bowel Syndrome with Constipation in six European countries: a 12-month observational study. En prensa. 2015.
24. Sun SX, DiBonaventura M, Purayidathil FW, Wagner J-S, Dabbous O, Mody R. Impact of Chronic Constipation on Health-Related Quality of Life, Work Productivity, and Healthcare Resource Use: An Analysis of the National Health and Wellness Survey. Digestive Diseases and Sciences. 2011;56(9):2688-95. PMID: 21380761.
25. Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. Pharmacoeconomics. 2005;23(5):461-76. PMID: 15896098.
26. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. Alimentary Pharmacology & Therapeutics. 2010;31(9):938-49. PMID: 20180788.
27. Drossman DA, Chang L, Bellamy N, Gallo-Torres HE, Lembo A, Mearin F, et al. Severity in Irritable Bowel Syndrome: A Rome Foundation Working Team Report. American Journal of Gastroenterology. 2011;106(10):1749-59. PMID: 21747417.
28. Mearin F, Lacy BE. Diagnostic criteria in IBS: useful or not? Neurogastroenterology and Motility. 2012;24(9):791-801. PMID: 22908861.
29. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Alimentary Pharmacology & Therapeutics. 1997;11(2):395-402. PMID: 9146781.
30. Almansa C, García R, Barceló M, Díaz-Rubio M, Rey E. Translation, cultural adaptation and validation of a Spanish version of the Irritable Bowel Syndrome Severity Score. Revista Espanola De Enfermedades Digestivas. 2011;103(12):612-8. PMID: 22217344.
31. Brandt LJ, Schoenfeld P, Prather CM, Quigley EMM, Schiller LR, Talley NJ, et al. Evidence-based position statement on the management of chronic constipation in North America. American Journal of Gastroenterology. 2005;100(1).
32. Bharucha AE, Wald A, Enck P, Rao S. Functional anorectal disorders. Gastroenterology. 2006;130(5):1510-8. PMID: 16678564.
33. Bharucha AE, Dorn SD, Lembo A, Pressman A, American Gastroenterological A. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013;144(1):211-7. PMID: 23261064.
34. Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG Clinical Guideline: Management of Benign Anorectal Disorders. American Journal of Gastroenterology. 2014;109(8):1141-57. PMID: 25022811.
35. Rao SSC, Meduri K. What is necessary to diagnose constipation? Best Practice & Research in Clinical Gastroenterology. 2011;25(1):127-40. PMID: 21382584.
36. Videlock EJ, Lembo A, Cremonini F. Diagnostic testing for dyssynergic defecation in chronic constipation: meta-analysis. Neurogastroenterology and Motility. 2013;25(6):PMID: 23644388.
37. Minguez M, Herreros B, Sanchiz V, Hernandez V, Almela P, Anon R, et al. Predictive value of the balloon expulsion test for excluding the diagnosis of pelvic floor dyssynergia in constipation. Gastroenterology. 2004;126(1):57-62. PMID: 14699488.
38. Tack J, Mueller-Lissner S, Stanghellini V, Boeckxstaens G, Kamm MA, Simren M, et al. Diagnosis and treatment of chronic constipation - a European perspective. Neurogastroenterology and Motility. 2011;23(8):697-710. PMID: 21605282.
39. Measurement of colonic transit time (total and segmental) with radiopaque markers. National reference values obtained in 192 healthy subjects. Spanish Group for the Study of Digestive Motility. Gastroenterologia y hepatologia. 1998;21(2):71-5. PMID: 9549181.
40. Bonapace ES, Maurer AH, Davidoff S, Krevsky B, Fisher RS, Parkman HP. Whole gut transit scintigraphy in the clinical evaluation of patients with upper and lower gastrointestinal symptoms. American Journal of Gastroenterology. 2000;95(10):2838-47. PMID: 11051357.
41. Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. Journal of Nuclear Medicine. 1997;38(11):1807-10. PMID: 9374360.
42. Camilleri M, Thorne NK, Ringel Y, Hasler WL, Kuo B, Esfandyari T, et al. Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterology and Motility. 2010;22(8):874-E233. PMID: 20465593.
43. Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation. Gastroenterology. 2005;129(1):86-97. PMID: 16012938.
44. Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology. 2006;130(3):657-64. PMID: 16530506.
45. Rao SSC, Seaton K, Miller M, Brown K, Nygaard I, Stumbo P, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clinical Gastroenterology and Hepatology. 2007;5(3):331-8. PMID: 17368232.
46. Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Diseases of the Colon & Rectum. 2007;50(4):428-41. PMID: 17294322.
47. Kamm MA, Dudding TC, Melenhorst J, Jarrett M, Wang Z, Buntzen S, et al. Sacral nerve stimulation for intractable constipation. Gut. 2010;59(3):333-40. PMID: 20207638.
48. Arebi N, Kalli T, Howson W, Clark S, Norton C. Systematic review of abdominal surgery for chronic idiopathic constipation. Colorectal Disease. 2011;13(12):1335-43. PMID: 20969711.
49. Bove A, Bellini M, Battaglia E, Bocchini R, Gambaccini D, Bove V, et al. Consensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (Part II: Treatment). World Journal of Gastroenterology. 2012;18(36):4994-5013. PMID: 23049207.
50. Muller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. American Journal of Gastroenterology. 2005;100(1):232-42. PMID: 15654804.
51. Moylan S, Armstrong J, Diaz-Saldano D, Saker M, Yerkes EB, Lindgren BW. Are Abdominal X-Rays a Reliable Way to Assess for Constipation? Journal of Urology. 2010;184(4):1692-7. PMID: 20728159.
52. Pensabene L, Buonomo C, Fishman L, Chitkara D, Nurko S. Lack of Utility of Abdominal X-rays in the Evaluation of Children With Constipation: Comparison of Different Scoring Methods. Journal of Pediatric Gastroenterology and Nutrition. 2010;51(2):155-9. PMID: 20453675.
53. Patriquin H, Martelli H, Devroede G. BARIUM ENEMA IN CHRONIC CONSTIPATION - IS IT MEANINGFUL. Gastroenterology. 1978;75(4):619-22. PMID: 710831.
54. Pepin C, Ladabaum U. The yield of lower endoscopy in patients with constipation: survey of a university hospital, a public county hospital, and a Veterans Administration medical center. Gastrointestinal Endoscopy. 2002;56(3):325-32. PMID: 12196767.
55. Gupta M, Holub J, Knigge K, Eisen G. Constipation is not associated with an increased rate of findings on colonoscopy: results from a national endoscopy consortium. Endoscopy. 2010;42(3):208-12. PMID: 20101567.
56. Mertz H, Naliboff B, Mayer EA. Symptoms and physiology in severe chronic constipation. American Journal of Gastroenterology. 1999;94(1):131-8. PMID: 9934743.
57. Eltringham MT, Khan U, Bain IM, Wooff DA, Mackie A, Jefferson E, et al. Functional defecation disorder as a clinical subgroup of chronic constipation: Analysis of symptoms and physiological parameters. Scandinavian Journal of Gastroenterology. 2008;43(3):262-9. PMID: 18266173.
58. Koch A, Voderholzer WA, Klauser AG, MullerLissner S. Symptoms in chronic constipation. Diseases of the Colon & Rectum. 1997;40(8):902-6. PMID: 9269805.
59. Orkin BA, Sinykin SB, Lloyd PC. The Digital Rectal Examination Scoring System (DRESS). Diseases of the Colon & Rectum. 2010;53(12):1656-60. PMID: 21178861.
60. Tantiphlachiva K, Rao P, Attaluri A, Rao SSC. Digital rectal examination is a useful tool for identifying patients with dyssynergia. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2010;8(11):955-60. PMID: 20656061.
61. Glia A, Lindberg G, Nilsson LH, Mihocsa L, Akerlund JE. Clinical value of symptom assessment in patients with constipation. Diseases of the Colon & Rectum. 1999;42(11):1401-8. PMID: 10566527.
62. Saad RJ, Rao SSC, Koch KL, Kuo B, Parkman HP, McCallum RW, et al. Do Stool Form and Frequency Correlate With Whole-Gut and Colonic Transit? Results From a Multicenter Study in Constipated Individuals and Healthy Controls. American Journal of Gastroenterology. 2010;105(2):403-11. PMID: 19888202.
63. Lam TJ, Felt-Bersma RJF. Clinical examination remains more important than anorectal function tests to identify treatable conditions in women with constipation. International Urogynecology Journal. 2013;24(1):67-72. PMID: 22618205.
64. Saha L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World Journal of Gastroenterology. 2014;20(22):6759-73. PMID: 24944467.
65. De Schryver AM, Keulemans YC, Peters HP, Akkermans LM, Smout AJ, De Vries WR, et al. Effects of regular physical activity on defecation pattern in middle-aged patients complaining of chronic constipation. Scandinavian Journal of Gastroenterology. 2005;40(4):422-9. PMID: 16028436.
66. Villoria A, Serra J, Azpiroz F, Malagelada J-R. Physical activity and intestinal gas clearance in patients with bloating. American Journal of Gastroenterology. 2006;101(11):2552-7. PMID: 17029608.
67. Dainese R, Serra J, Azpiroz F, Malagelada JR. Effects of physical activity on intestinal gas transit and evacuation in healthy subjects. American Journal of Medicine. 2004;116(8):536-9. PMID: 15063815.
68. Johannesson E, Ringstrom G, Abrahamsson H, Sadik R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World Journal of Gastroenterology. 2015;21(2):600-8. PMID: 25593485.
69. Johannesson E, Simren M, Strid H, Bajor A, Sadik R. Physical Activity Improves Symptoms in Irritable Bowel Syndrome: A Randomized Controlled Trial. American Journal of Gastroenterology. 2011;106(5):915-22. PMID: 21206488.
70. Ternent CA, Amir LB, Morin NA, Ellis CN, Hyman NH, Buie WD, et al. Practice parameters for the evaluation and management of constipation. Diseases of the Colon & Rectum. 2007;50(12):2013-22. PMID: 17665250.
71. Remes Troche JM, Gomez Escudero O, Icaza Chavez ME, Noble Lugo A, Lopez Colombo A, Bielsa MV, et al. Guidelines for diagnosis and treatment of constipation in Mexico. C) Medical and surgical treatment. Revista de gastroenterologia de Mexico. 2011;76(2):141-54. PMID: 21724490.
72. Gallegos-Orozco JF, Foxx-Orenstein AE, Sterler SM, Stoa JM. Chronic Constipation in the Elderly. American Journal of Gastroenterology. 2012;107(1):18-25. PMID: 21989145.
73. Anti M, Pignataro G, Armuzzi A, Valenti A, Iascone E, Marino R, et al. Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation. Hepato-Gastroenterology. 1998;45(21):727-32. PMID: 9684123.
74. Lever E, Cole J, Scott SM, Emery PW, Whelan K. Systematic review: the effect of prunes on gastrointestinal function. Alimentary Pharmacology & Therapeutics. 2014;40(7):750-8. PMID: 25109788.
75. Bijkerk CJ, Muris JWM, Knottnerus JA, Hoes AW, De Wit NJ. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2004;19(3):245-51. PMID: 14984370.
76. Ford AC, Talley NJ, Spiegel BMR, Foxx-Orenstein AE, Schiller L, Quigley EMM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. British Medical Journal. 2008;337:PMID: 19008265.
77. Carroccio A, Mansueto P, Iacono G, Soresi M, D'Alcamo A, Cavataio F, et al. Non-Celiac Wheat Sensitivity Diagnosed by Double-Blind Placebo-Controlled Challenge: Exploring a New Clinical Entity. American Journal of Gastroenterology. 2012;107(12):1898-906. PMID: 22825366.
78. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No Effects of Gluten in Patients With Self-Reported Non-Celiac Gluten Sensitivity After Dietary Reduction of Fermentable, Poorly Absorbed, Short-Chain Carbohydrates. Gastroenterology. 2013;145(2):320-+. PMID: 23648697.
79. Brandt LJ, Chey WD, Foxx-Orenstein AE, Quigley EMM, Schiller LR, Schoenfeld PS, et al. An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome. American Journal of Gastroenterology. 2009;104:S1-S36. PMID: 19521341.
80. Staudacher HM, Lomer MCE, Anderson JL, Barrett JS, Muir JG, Irving PM, et al. Fermentable Carbohydrate Restriction Reduces Luminal Bifidobacteria and Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome. Journal of Nutrition. 2012;142(8):1510-8. PMID: 22739368.
81. Boehn L, Stoersrud S, Liljebo TM, Lindfors P, Toernblom H, Simren M. A Randomized, Controlled Trial Comparing a Diet Low in FODMAPs With Traditional Dietary Advice in Patients With IBS. Gastroenterology. 2015;148(4):S654-S. PMID: 26255043.
82. Stephen AM, Cummings JH. MECHANISM OF ACTION OF DIETARY FIBER IN THE HUMAN-COLON. Nature. 1980;284(5753):283-4. PMID: 7360261.
83. Rao SSC, Yu S, Fedewa A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2015;41(12):1256-70. PMID: 25903636.
84. Yang J, Wang H-P, Zhou L, Xu C-F. Effect of dietary fiber on constipation: A meta analysis. World Journal of Gastroenterology. 2012;18(48):7378-83. PMID: 23326148.
85. Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Alimentary Pharmacology & Therapeutics. 2011;33(8):895-901. PMID: 21332763.
86. Francis CY, Whorwell PJ. BRAN AND IRRITABLE-BOWEL-SYNDROME - TIME FOR REAPPRAISAL. Lancet. 1994;344(8914):39-40. PMID: 7912305.
87. Voderholzer WA, Schatke W, Muhldorfer BE, Klauser AG, Birkner B, MullerLissner SA. Clinical response to dietary fiber treatment of chronic constipation. American Journal of Gastroenterology. 1997;92(1):95-8. PMID: 8995945.
88. Awad RA, Camacho S. A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome. Colorectal Disease. 2010;12(11):1131-8. PMID: 19575740.
89. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized Clinical Trial: Macrogol/PEG 3350 Plus Electrolytes for Treatment of Patients With Constipation Associated With Irritable Bowel Syndrome. American Journal of Gastroenterology. 2013;108(9):1508-15. PMID: 23835436.
90. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. American Journal of Gastroenterology. 2014;109:S2-S26. PMID: 25091148.
91. Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus Polyethylene Glycol for Chronic Constipation. Cochrane Database of Systematic Reviews. 2010(7):PMID: 20614462.
92. Hookway C, Buckner S, Crosland P, Longson D. Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance. Bmj-British Medical Journal. 2015;350:PMID: 25716701.
93. Kamm MA, Mueller-Lissner S, Wald A, Richter E, Swallow R, Gessner U. Oral Bisacodyl Is Effective and Well-Tolerated in Patients With Chronic Constipation. Clinical Gastroenterology and Hepatology. 2011;9(7):577-83. PMID: 21440672.
94. Mueller-Lissner S, Kamm MA, Wald A, Hinkel U, Koehler U, Richter E, et al. Multicenter, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Sodium Picosulfate in Patients With Chronic Constipation. American Journal of Gastroenterology. 2010;105(4):897-903. PMID: 20179697.
95. Bernet MF, Brassart D, Neeser JR, Servin AL. LACTOBACILLUS-ACIDOPHILUS LA-1 BINDS TO CULTURED HUMAN INTESTINAL-CELL LINES AND INHIBITS CELL ATTACHMENT AND CELL INVASION BY ENTEROVIRULENT BACTERIA. Gut. 1994;35(4):483-9. PMID: 8174985.
96. Wang XD, Soltesz V, Molin G, Andersson R. THE ROLE OF ORAL-ADMINISTRATION OF OATMEAL FERMENTED BY LACTOBACILLUS-REUTERI R2LC ON BACTERIAL TRANSLOCATION AFTER ACUTE LIVER-FAILURE INDUCED BY SUBTOTAL LIVER RESECTION IN THE RAT. Scandinavian Journal of Gastroenterology. 1995;30(2):180-5. PMID: 7732342.
97. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. ENHANCEMENT OF THE CIRCULATING ANTIBODY SECRETING CELL RESPONSE IN HUMAN DIARRHEA BY A HUMAN LACTOBACILLUS STRAIN. Pediatric Research. 1992;32(2):141-4. PMID: 1324462.
98. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo FY, Chen KS, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541-51. PMID: 15765388.
99. Ford AC, Quigley EMM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis. American Journal of Gastroenterology. 2014;109(10):1547-61. PMID: 25070051.
100. Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJF. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Canadian Journal of Gastroenterology. 2003;17(11):655-9. PMID: 14631461.
101. Pimentel M, Chang C, Chua KS, Mirocha J, DiBaise J, Rao S, et al. Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome. Digestive Diseases and Sciences. 2014;59(6):1278-85. PMID: 24788320.
102. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome - A randomized trial. Annals of Internal Medicine. 2006;145(8):557-63. PMID: 17043337.
103. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. New England Journal of Medicine. 2011;364(1):22-32. PMID: 21208106.
104. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: A double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology. 2003;98(2):412-9. PMID: 12591062.
105. Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome - art. no. CD003460.pub2. Cochrane Database of Systematic Reviews. 2005(2):PMID: 15846668.
106. Clave P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2011;34(4):432-42. PMID: 21679214.
107. Capanni M, Surrenti E, Biagini M, Milani S, Surrenti C, Galli A. Efficacy of peppermint oil in the treatment of irritable bowel syndrome: a randomized, controlled trial. Gazzetta Medica Italiana. 2005(164):119-26.
108. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil((R))) in the treatment of irritable bowel syndrome: A prospective double blind placebo-controlled randomized trial. Digestive and Liver Disease. 2007;39(6):530-6. PMID: 17420159.
109. Lech Y, Olesen KM, Hey H, Rask-Pedersen E, Vilien M, Ostergaard O. Treatment of irritable bowel syndrome with peppermint oil. A double-blind study with a placebo. Ugeskrift for laeger. 1988;150(40):2388-9. PMID: 3061106.
110. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: A prospective, randomized trial. Journal of Gastroenterology. 1997;32(6):765-8. PMID: 9430014.
111. Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The Effect of Enteric-Coated, Delayed-Release Peppermint Oil on Irritable Bowel Syndrome. Digestive Diseases and Sciences. 2010;55(5):1385-90. PMID: 19507027.
112. Kim DY, Camilleri M. Serotonin: A mediator of the brain-gut connection. American Journal of Gastroenterology. 2000;95(10):2698-709. PMID: 11051338.
113. Bassotti G, Blandizzi C. Understanding and treating refractory constipation. World journal of gastrointestinal pharmacology and therapeutics. 2014;5(2):77-85. PMID: 24868488.
114. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. New England Journal of Medicine. 2008;358(22):2344-54. PMID: 18509121.
115. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58(3):357-65. PMID: 18987031.
116. Quigley EMM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Alimentary Pharmacology & Therapeutics. 2009;29(3):315-28. PMID: 19035970.
117. Shin A, Camilleri M, Kolar G, Erwin P, West CP, Murad MH. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Alimentary Pharmacology & Therapeutics. 2014;39(3):239-53. PMID: 24308797.
118. Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterology and Motility. 2009;21(12):PMID: 19751247.
119. Emmanuel AV, Kamm MA, Roy AJ, Kerstens R, Vandeplassche L. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, cross-over, multiple n=1 study. Alimentary Pharmacology & Therapeutics. 2012;35(1):48-55. PMID: 22061077.
120. Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. European Journal of Pharmacology. 2010;649(1-3):328-35. PMID: 20863829.
121. Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterology and Motility. 2010;22(3):PMID: 19706070.
122. Videlock EJ, Cheng V, Cremonini F. Effects of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation: A Meta-analysis. Clinical Gastroenterology and Hepatology. 2013;11(9):1084-U82. PMID: 23421551.
123. Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and metaanalysis. Neurogastroenterology and Motility. 2014;26(4):499-509. PMID: 24351035.
124. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011;60(2):209-18. PMID: 21205879.
125. Wilson N, Schey R. Lubiprostone in constipation: clinical evidence and place in therapy. Therapeutic advances in chronic disease. 2015;6(2):40-50. PMID: 25729555.
126. Woodward S, Norton C, Chiarelli P. Biofeedback for treatment of chronic idiopathic constipation in adults. Cochrane Database of Systematic Reviews. 2014(3):PMID: 24668156.
127. Rao SSC, Benninga MA, Bharucha AE, Chiarioni G, Di Lorenzo C, Whitehead WE. ANMS-ESNM position paper and consensus guidelines on biofeedback therapy for anorectal disorders. Neurogastroenterol Motil. 2015;27(5):594-609. PMID: 25828100.
128. Ford AC, Talley NJ, Schoenfeld PS, Quigley EMM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58(3):367-78. PMID: 19001059.
129. Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Alimentary Pharmacology & Therapeutics. 2005;22(5):381-5. PMID: 16128675.
130. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55(8):1095-103. PMID: 16401691.
131. Masand PS, Pae C-U, Krulewicz S, Peindl K, Mannelli P, Varia IM, et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Paroxetine Controlled-Release in Irritable Bowel Syndrome. Psychosomatics. 2009;50(1):78-86. PMID: 19213976.
132. Brennan BP, Fogarty KV, Roberts JL, Reynolds KA, Pope HG, Jr., Hudson JI. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Human Psychopharmacology-Clinical and Experimental. 2009;24(5):423-8. PMID: 19548294.
133. Colonna L. Antidepresseurs. In: Flammarion MS, editor. Vassilis Kapsambelis D Ginestet:  Thérapeutique médicamenteuse des troubles psychiatriques de l'adulte. París1996. p. 29-41.
134. Liu JP, Yang M, Lix YX, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews. 2006(1):PMID: 16437473.
135. Park HJ, Jarrett M, Cain K, Heitkemper M. Psychological distress and GI symptoms are related to severity of bloating in women with irritable bowel syndrome. Research in Nursing & Health. 2008;31(2):98-107. PMID: 18181134.
136. Blanchard EB, Lackner JM, Jaccard J, Rowell D, Carosella AM, Powell C, et al. The role of stress in symptom exacerbation among IBS patients. Journal of Psychosomatic Research. 2008;64(2):119-28. PMID: 18222125.
137. Choung RS, Locke GR, III, Zinsmeister AR, Schleck CD, Talley NJ. Psychosocial Distress and Somatic Symptoms in Community Subjects With Irritable Bowel Syndrome: A Psychological Component Is the Rule. American Journal of Gastroenterology. 2009;104(7):1772-9. PMID: 19491833.
138. Lindfors P, Unge P, Arvidsson P, Nyhlin H, Bjornsson E, Abrahamsson H, et al. Effects of Gut-Directed Hypnotherapy on IBS in Different Clinical Settings-Results From Two Randomized, Controlled Trials. American Journal of Gastroenterology. 2012;107(2):276-85. PMID: 21971535.
139. Webb AN, Kukuruzovic RH, Catto-Smith AG, Sawyer SM. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews. 2007(4):PMID: 17943840.
140. Dorsher P, Fleckenstein J. Puntos gatillo y puntos de acupuntura clásica. Parte 2: Correspondencias clínicas en el tratamiento del dolor y las disfunciones somatoviscerales. Revista Internacional de Acupuntura. 2009;36(2).
141. Manheimer E, Wieland LS, Cheng K, Li SM, Shen X, Berman BM, et al. Acupuncture for Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. American Journal of Gastroenterology. 2012;107(6):835-47. PMID: 22488079.
142. Lembo AJ, Conboy L, Kelley JM, Schnyer RS, McManus CA, Quilty MT, et al. A Treatment Trial of Acupuncture in IBS Patients. American Journal of Gastroenterology. 2009;104(6):1489-97. PMID: 19455132.
143. Hussain ZH, Whitehead DA, Lacy BE. Fecal impaction. Current gastroenterology reports. 2014;16(9):404-. PMID: 25119877.
144. Christensen P, Bazzocchi G, Coggrave M, Abel R, Hultling C, Krogh K, et al. A randomized, controlled trial of transanal irrigation versus conservative bowel management in spinal cord-injured patients. Gastroenterology. 2006;131(3):738-47. PMID: 16952543.
145. Del Popolo G, Mosiello G, Pilati C, Lamartina M, Battaglino F, Buffa P, et al. Treatment of neurogenic bowel dysfunction using transanal irrigation: a multicenter Italian study. Spinal Cord. 2008;46(7):517-22. PMID: 18317488.
146. Christensen P, Andreasen J, Ehlers L. Cost-effectiveness of transanal irrigation versus conservative bowel management for spinal cord injury patients. Spinal Cord. 2009;47(2):138-43. PMID: 18679401.
147. Podzemny V, Pescatori LC, Pescatori M. Management of obstructed defecation. World Journal of Gastroenterology. 2015;21(4):1053-60. PMID: 25632177.
148. Mowatt G, Glazener C, Jarrett M. Sacral nerve stimulation for faecal incontinence and constipation in adults. Cochrane Database of Systematic Reviews. 2007(3):PMID: 17636759.
149. Mínguez M, Mora F, Mas P. Guía práctica de actuación diagnóstico-terapéutica en estreñimiento crónico. Valencia: Fundación Española de Aparato Digestivo; 2013.
150. Fukudo S, Kaneko H, Akiho H, Inamori M, Endo Y, Okumura T, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome. Journal of Gastroenterology. 2015;50(1):11-30. PMID: 25500976.
151. Chey WD, Kurlander J, Eswaran S. Irritable Bowel Syndrome A Clinical Review. Jama-Journal of the American Medical Association. 2015;313(9):949-58. PMID: 25734736.
152. Grupo de trabajo de la guía de práctica clínica sobre el síndrome del intestino irritable. Manejo del paciente con síndrome del intestino irritable. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2005.
153. Grupo de Trabajo de la Guía de Práctica Clínica sobre el manejo del estreñimiento crónico en el paciente adulto. Guía de práctica clínica. En prensa. 2015
Related articles

Special Article

Consensus document on exclusion diets in irritable bowel syndrome (IBS)

DOI: 10.17235/reed.2018.5941/2018

Editorial

On the centenary of The Spanish Journal of Gastroenterology (REED)

DOI: 10.17235/reed.2017.5427/2017

Editorial

Gastroenterology, a historical specialty with a great future

DOI: 10.17235/reed.2017.5193/2017

Citation tools
Mearin F, Ciriza C, Mínguez M, Rey E, Mascort J, Peña E, et all. Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult. 4389/2016


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 23236 visits.
This article has been downloaded 4255 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 17/04/2016

Accepted: 19/04/2016

Online First: 27/05/2016

Published: 03/06/2016

Article Online First time: 40 days

Article editing time: 47 days


Share
This article has been rated by 15 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology